Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Clinical Trial FAQs About Us
Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA088-1007  |   NCT06615479

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • 84
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Participants must have relapsed or refractory multiple myeloma (RRMM).
    1. Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.
      1. Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
        1. Participants must have measurable disease during screening.
          1. Participants must have adequate organ function.
            1. Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.

              Exclusion Criteria

              Exclusion Criteria Icon
              • Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).
                1. Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
                  1. Participants must not need urgent treatment due to rapidly progressing MM.
                    Additional Information *
                    • Other protocol-defined Inclusion/Exclusion criteria apply.

                      Treatment Options

                      Study Arms

                      ASSIGNED INTERVENTION

                      Study Arms

                      Experimental: Arm A

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986393, Cyclophosphamide, Fludarabine, Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib

                      Study Arms

                      Active Comparator: Arm B

                      ASSIGNED INTERVENTION
                      • Drug: Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib
                      Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                      Check Your Eligibility
                      Answer some questions about Your health to see if you may match to this trial
                      Match to a Trial
                      If you are a match, click on the study to see the list of study site locations
                      Select a Study Site Location
                      Select a study site location that is convenient for you
                      Register
                      Provide your contact details for the study site to connect with you.

                      Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you